ImmunoCellular Therapeutics (OTC BB: IMUC) has added NBS’s subsidiary, Progenitor Cell Therapy (PCT) as a 2nd manufacturing site Read more…
NYSE Amex: NBS changed its previously announced presentation at the 6th Annual JMP Securities Healthcare Conference. Read more…
The award is being made Read more…
NeoStem announced, 7/14/11, the acquisition of Amorcyte; AMR-001, with a P2 study for the treatment of acute myocardial infarction (AMI). Read more…
NYSE-Amex: NBS to sell shares of its common stock and warrants in a public offering. Read more…
Amorcyte is a development stage cell therapy company focusing on novel treatments for cardiovascular disease. Read more…
Cardinal Gianfranco Ravasi, President of the Pontifical Council for Culture, Dr. Robin L. Smith, Chairman/CEO of NBS, and Reverend Tomasz Trafny, Head of the Science and Faith Department at the Pontifical Council for Culture provided details Read more…
VSELs may represent the “Holy Grail” of stem cell therapy, a natural “pluripotent”. Read more…
Q1/11 net loss of $9.69 M or $0.14 per share Read more…
NBS’s Progenitor Cell Therapy (PCT), a wholly owned subsidiary is in compliance with FACT-JACIE Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.